arrow
Á

Álvaro Taus

institut hospital del mar d’investigacions mèdiques
H指数:25
被引数:1,817

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review

免疫检查点抑制剂相关心肌炎、肌炎和重症肌无力重叠综合征:单中心病例系列和系统综述

2026-10-150
PRE
Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study

免疫疗法治疗KRAS G12C突变与非G12C突变非小细胞肺癌的临床结局:一项多中心真实世界研究

2026-08-070
OAAI
Clinical outcomes and subsequent therapy in patients with platinum-sensitive recurrent ovarian cancer deriving long-term benefit from maintenance niraparib: a subgroup analysis of the GEICO-88R study

铂敏感复发性卵巢癌患者从 niraparib 维持治疗中获得长期获益的临床结局与后续治疗:GEICO-88R 研究的亚组分析

2025-08-160
PRE
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer

MET通路抑制可增强小细胞肺癌的化疗-免疫治疗疗效

2025-06-200
OAAI
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade

接受免疫检查点阻断的转移性NSCLC患者的分子和免疫学特征与长期获益相关

2025-02-240
OA
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗治疗复发和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的2期研究

2024-11-011
PRE
Spatial proteomic profiling unveils pre-existing anti-tumor immunity as a hallmark of exceptional benefit from immunotherapy in NSCLC
2024-03-220
PRE
Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer
2023-10-202
OAAI
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study
2022-11-088
OAAI
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
2022-10-265
OA
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
2020-10-2643
OAAI
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study

Afatinib在非小细胞肺癌患者中具有罕见EGFR突变的临床活性: 西班牙回顾性多中心研究

2020-09-0118
PREAI